Categories: News

Xcelerate, Inc. Unveils Website That Crosses the Divide Between Non-Medical Engineering and Clinical Care

MAULDIN, S.C., April 29, 2021 /PRNewswire/ — Xcelerate, Inc. (OTC: “XCRT”), unveiled an innovative website www.xcelerate.global encompassing its emergence as a leader in bringing together advanced engineering solutions, MedTech producers and clinical care settings into a unified, productive system.

The new Xcelerate website will communicate the company’s mission, growth, success, and the full potential of MedTech development and healthcare delivery.  The site will serve as a platform for publishing Xcelerate’s latest developments and news while sharing its Twitter feed @XcelerateUS. The website also will explain more about the inner workings of Xcelerate and its expanding board of distinguished advisors, as well as the growing company’s directors, science officer and counsel.

“The unveiling of the official website for Xcelerate, Inc. is a huge step toward achieving our mission of bridging the gap between advanced engineering and medicine,” said Chief Executive Officer and Director of Xcelerate, Inc. Michael O’Shea. “We chose dot global, not dot com because Xcelerate is a global company, and we look forward to keep growing,” O’Shea added.

For more information on Xcelerate, Inc, please visit www.xcelerate.global. and follow them on Twitter @XcelerateUS.  Media contact: Justin Baronoff 561-750-9800; justin@transmediagroup.com.

ABOUT XCELERATE
Xcelerate is a company seeking innovative acquisitions within the patent/engineering world and focused on joining early-stage medical technology companies in a setting that is a controlled clinical care where these new developments can be trailed, tested, and applied.

Media Contact: Justin Baronoff, justin@transmediagroup.com  (561) 750-9800

View original content:http://www.prnewswire.com/news-releases/xcelerate-inc-unveils-website-that-crosses-the-divide-between-non-medical-engineering-and-clinical-care-301280109.html

SOURCE Xcelerate, Inc.

Staff

Recent Posts

Vivos Inc.’s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide

Richland, WA, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to…

1 hour ago

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing…

1 hour ago

Optinose Announces 1-for-15 Reverse Stock Split

YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company…

1 hour ago

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage…

1 hour ago

Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute

Company recently signed a non-binding term sheet with Dr Glitter Pty Ltd for mutual development…

1 hour ago

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

TEL AVIV, Israel, Dec. 26, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or…

1 hour ago